Teva — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical leader with a dual strategy of being a generics/biosimilars powerhouse and an innovative specialty medicines developer. Its mission, 'We are all in for better health,' is executed through a focus on neuroscience and immunology, leveraging strategic partnerships and a robust pipeline. The company is currently in the 'Acceleration Phase' of its 'Pivot to Growth' plan, aiming for consistent financial performance and pipeline execution, having delivered three consecutive years of growth as of 2025.

NeuroscienceImmunology

Technology Platform

Teva's platform is an integrated commercial and development engine built on world-class expertise in complex chemistry, manufacturing, and controls (CMC) for small molecules and biologics, enabling a dual strategy of generics/biosimilars production and targeted innovative drug development.

Opportunities

Teva is poised to capitalize on the global biosimilars wave targeting multi-billion dollar originator biologics, while its focused innovative pipeline addresses large, underserved markets in neuroscience and immunology.

Its hybrid model provides financial stability to fund growth initiatives.

Risk Factors

Key risks include pipeline execution failures in late-stage trials, chronic pricing pressure in the generics sector, ongoing legal and regulatory liabilities from past litigation, and the challenge of integrating external innovation from partnerships.

Competitive Landscape

In generics/biosimilars, Teva competes on scale and cost with Viatris and Sandoz. In innovative specialties, it faces large pharma (AbbVie, J&J) and biotech firms, differentiating through CNS expertise and a capital-efficient partnership model.

More companies in Biologics / Biosimilars →More companies in United States →